A high-profile researcher has issued what is now one of many public challenges to the manner in which the FDA speeds approval of certain drugs. Researcher Dr. Clifford J. Rosen is concerned, in
Shares of Trubion got whacked yesterday after investors and analysts got to take a second look at the data from its mid-stage study of its lead therapy for rheumatoid arthritis--TRU-015--and the news
After laying off most of its staff earlier this year during a cash crunch, Madison, WI-based OpGen has received a $23.6 million shot in the arm that will allow the biotech to "restart" operations.
Canada's Biomira plans to reincorporate in the U.S., headquartering its parent company in Seattle. CEO Robert Kirkman says the relocation to the U.S. will raise the company's profile in U.S.
CytRx Corporation has appointed Mitchell K. Fogelman as chief financial officer, effective immediately, replacing Matthew Natalizio, who plans to pursue other opportunities. Clarus Ventures
> France's Flamel Technologies gets an undisclosed upfront payment and a schedule of potential milestone payments after signing a licensing and development deal with Wyeth for using its technology
ImClone once again is feeling the tonic effects of positive trial data. Its stock price took off this morning, rising 19 percent after its European partner, Merck KGaA, reported that Erbitux helped
The vast majority of Phase II cancer therapies go nowhere, according to researchers investigating the fate of 200 drug trials. Only 13 percent of the cancer drugs make it to Phase III, they say, with
Nabi Biopharmaceuticals plans to sell its biologics unit to Germany's Biotest for $185 million. Biotest gains a headquarters facility in Boca Raton, a plasma protein plant, Nabi-HB Hepatitis B immune
Canada's Enobia Pharma has raised $40.1 million Canadian in its second round, enough money to get its lead therapy through Phase II. New investors OrbiMed Advisors and CTI Life Sciences Fund of
Deal-making continued at a blistering pace in the first half of 2007, as drug giants snapped up promising therapies from smaller developers in order to beef up their pipelines. Check out this report
> GlaxoSmithKline has signed on to commercialize Sepracor's insomnia drug Lunesta, agreeing to pay $20 million up front and up to $155 million in total for milestones and licensing fees. Glaxo
The venture capital firm Azimuth Opportunity has agreed to buy up to $100 million of Medivation's stock over the next 18 months as the drug developer pushes through a late-stage trial of an